TDMS Study 05158-04 Pathology Tables
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:23
Facility: Battelle Northwest
Chemical CAS #: 1313-27-5
Lock Date: 07/13/93
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 50 50 50 50
Early Deaths
Moribund Sacrifice 17 12 14 10
Natural Death 8 6 2 5
Accidently Killed 1 1
Survivors
Terminal Sacrifice 24 31 31 35
Moribund Sacrifice 1 2
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Esophagus (50) (50) (49) (50)
Inflammation 2 (4%) 1 (2%)
Epithelium, Hyperplasia 1 (2%)
Gallbladder (40) (44) (46) (41)
Cyst 1 (2%)
Inflammation, Suppurative 1 (3%) 1 (2%)
Intestine Small, Duodenum (43) (46) (47) (46)
Epithelium, Hyperplasia 1 (2%)
Peyer's Patch, Hyperplasia 1 (2%)
Intestine Small, Jejunum (44) (45) (47) (46)
Epithelium, Hyperplasia 1 (2%)
Peyer's Patch, Hyperplasia 2 (4%)
Intestine Small, Ileum (45) (45) (47) (46)
Peyer's Patch, Hyperplasia 1 (2%)
Liver (50) (50) (50) (49)
Angiectasis 1 (2%) 1 (2%)
Basophilic Focus 1 (2%) 1 (2%)
Degeneration, Fatty 1 (2%) 1 (2%)
Eosinophilic Focus 5 (10%) 15 (30%) 12 (24%) 4 (8%)
Hematopoietic Cell Proliferation 2 (4%) 3 (6%) 2 (4%)
Hepatodiaphragmatic Nodule 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%) 1 (2%)
Mixed Cell Focus 1 (2%)
Necrosis 5 (10%) 3 (6%) 2 (4%) 3 (6%)
Vacuolization Cytoplasmic 1 (2%) 1 (2%)
Bile Duct, Cyst 2 (4%) 1 (2%) 1 (2%)
Centrilobular, Degeneration 1 (2%) 2 (4%) 1 (2%)
Centrilobular, Hypertrophy 2 (4%)
Mesentery (4) (9) (9) (7)
Artery, Inflammation, Chronic 1 (11%)
Fat, Necrosis 3 (75%) 8 (89%) 5 (56%) 7 (100%)
Pancreas (50) (49) (48) (46)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Atrophy 3 (6%) 2 (4%) 4 (8%) 6 (13%)
Basophilic Focus 1 (2%) 1 (2%)
Hyperplasia 1 (2%) 2 (4%)
Hypertrophy 1 (2%) 1 (2%) 1 (2%)
Inflammation, Chronic 1 (2%)
Duct, Cyst 1 (2%) 2 (4%)
Stomach, Forestomach (50) (50) (49) (47)
Diverticulum 1 (2%)
Inflammation 1 (2%) 1 (2%) 1 (2%)
Inflammation, Suppurative 1 (2%)
Ulcer 2 (4%)
Epithelium, Hyperplasia 1 (2%) 3 (6%) 1 (2%) 3 (6%)
Stomach, Glandular (49) (49) (47) (46)
Inflammation, Chronic 1 (2%)
Necrosis 1 (2%)
Epithelium, Hyperplasia 1 (2%) 1 (2%)
Tooth (2)
Developmental Malformation 1 (50%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Blood Vessel (2)
Inflammation, Chronic 1 (50%)
Mineralization 1 (50%)
Heart (50) (50) (49) (49)
Cardiomyopathy 39 (78%) 42 (84%) 43 (88%) 43 (88%)
Mineralization 2 (4%) 1 (2%)
Artery, Inflammation 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (50) (49) (49)
Hematopoietic Cell Proliferation 2 (4%)
Hyperplasia 1 (2%) 3 (6%) 1 (2%) 2 (4%)
Hypertrophy 5 (10%) 3 (6%) 4 (8%) 6 (12%)
Adrenal Medulla (50) (49) (49) (49)
Hyperplasia 4 (8%) 5 (10%) 6 (12%) 3 (6%)
Islets, Pancreatic (50) (49) (48) (46)
Hyperplasia 4 (8%) 2 (4%) 1 (2%)
Parathyroid Gland (31) (39) (37) (33)
Hyperplasia 1 (3%)
Pituitary Gland (49) (48) (48) (49)
Pars Distalis, Hyperplasia 13 (27%) 23 (48%) 15 (31%) 17 (35%)
Pars Intermedia, Hyperplasia 1 (2%) 3 (6%) 1 (2%)
Thyroid Gland (50) (50) (49) (49)
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Inflammation, Chronic 1 (2%)
Follicular Cell, Hyperplasia 15 (30%) 16 (32%) 14 (29%) 18 (37%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Ovary (50) (49) (48) (46)
Angiectasis 1 (2%) 3 (6%) 2 (4%) 1 (2%)
Atrophy 5 (10%) 5 (10%) 6 (13%) 4 (9%)
Cyst 22 (44%) 15 (31%) 16 (33%) 11 (24%)
Degeneration, Fatty 1 (2%)
Hemorrhage 1 (2%)
Hyperplasia 1 (2%) 1 (2%) 1 (2%)
Inflammation, Chronic 1 (2%)
Metaplasia, Osseous 1 (2%)
Thrombosis 1 (2%)
Corpus Luteum, Hyperplasia 2 (4%) 1 (2%)
Interstitial Cell, Hyperplasia 2 (4%)
Uterus (50) (50) (49) (49)
Angiectasis 2 (4%) 2 (4%) 1 (2%) 3 (6%)
Hydrometra 1 (2%) 3 (6%) 4 (8%)
Hyperplasia, Cystic 2 (4%) 2 (4%) 3 (6%) 1 (2%)
Inflammation, Suppurative 1 (2%) 3 (6%) 3 (6%)
Thrombosis 1 (2%)
Endometrium, Hemorrhage 1 (2%)
Endometrium, Hyperplasia 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (49) (49)
Angiectasis 1 (2%)
Hyperplasia 1 (2%) 4 (8%)
Infiltration Cellular, Mast Cell 1 (2%)
Necrosis 1 (2%)
Lymph Node (4) (6) (7) (4)
Angiectasis 1 (17%) 2 (50%)
Iliac, Congestion 1 (25%)
Iliac, Hyperplasia 2 (50%) 2 (33%) 1 (14%) 1 (25%)
Lumbar, Hyperplasia 1 (14%)
Renal, Congestion 1 (25%)
Renal, Hyperplasia 1 (25%) 1 (17%) 1 (25%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Lymph Node, Bronchial (41) (32) (36) (31)
Hyperplasia 2 (5%) 3 (9%) 1 (3%) 4 (13%)
Lymph Node, Mandibular (39) (40) (43) (40)
Angiectasis 1 (3%)
Hyperplasia 2 (5%) 7 (18%) 6 (14%) 5 (13%)
Lymph Node, Mesenteric (49) (49) (46) (44)
Angiectasis 1 (2%)
Congestion 1 (2%) 1 (2%)
Hyperplasia 4 (8%) 8 (16%) 5 (11%) 5 (11%)
Lymph Node, Mediastinal (41) (41) (40) (41)
Hyperplasia 3 (7%) 5 (12%) 2 (5%) 4 (10%)
Spleen (50) (50) (49) (47)
Hematopoietic Cell Proliferation 16 (32%) 9 (18%) 18 (37%) 10 (21%)
Hyperplasia, Lymphoid 5 (10%) 11 (22%) 9 (18%) 9 (19%)
Infiltration Cellular, Mononuclear Cell 1 (2%)
Thymus (40) (35) (40) (37)
Atrophy 1 (3%) 1 (3%)
Hyperplasia, Lymphoid 2 (6%) 1 (3%) 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Mammary Gland (49) (49) (49) (50)
Hyperplasia 2 (4%) 1 (2%)
Skin (50) (50) (49) (50)
Inflammation, Chronic Active 1 (2%)
Inflammation, Focal, Granulomatous 1 (2%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Fibrous Osteodystrophy 25 (50%) 17 (34%) 19 (38%) 26 (52%)
Fracture 1 (2%) 1 (2%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (49) (49)
Gliosis 1 (2%)
Necrosis 1 (2%) 1 (2%)
Meninges, Inflammation, Chronic 3 (6%) 3 (6%) 2 (4%) 3 (6%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (49) (50) (49) (50)
Hyperplasia 1 (2%) 1 (2%) 7 (14%) 35 (70%)
Necrosis 1 (2%) 1 (2%)
Epiglottis, Hyperplasia 6 (12%) 1 (2%)
Epiglottis, Metaplasia 1 (2%)
Epiglottis, Metaplasia, Squamous 1 (2%) 36 (72%) 43 (88%) 49 (98%)
Epiglottis, Necrosis 2 (4%) 1 (2%)
Lung (50) (50) (49) (49)
Hemorrhage 1 (2%)
Infiltration Cellular, Histiocyte 5 (10%) 3 (6%) 2 (4%) 6 (12%)
Alveolar Epithelium, Hyperplasia 1 (2%) 3 (6%) 3 (6%) 6 (12%)
Alveolar Epithelium, Metaplasia 2 (4%) 26 (52%) 39 (80%) 46 (94%)
Perivascular, Infiltration Cellular 2 (4%)
Nose (49) (50) (49) (49)
Hemorrhage 1 (2%) 1 (2%)
Inflammation, Suppurative 8 (16%) 6 (12%) 6 (12%) 16 (33%)
Metaplasia, Squamous 1 (2%) 2 (4%)
Nasolacrimal Duct, Inflammation, Suppurative 1 (2%)
Olfactory Epithelium, Atrophy 5 (10%) 1 (2%) 4 (8%) 4 (8%)
Olfactory Epithelium, Degeneration, Hyaline 22 (45%) 14 (28%) 14 (29%) 36 (73%)
Respiratory Epithelium, Degeneration, Hyaline 26 (53%) 23 (46%) 28 (57%) 48 (98%)
Respiratory Epithelium, Necrosis 1 (2%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (1)
Retrobulbar, Inflammation, Suppurative 1 (100%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (50) (50) (49) (47)
Atrophy 1 (2%)
Hydronephrosis 1 (2%) 1 (2%)
Metaplasia, Osseous 1 (2%) 2 (4%) 2 (4%) 2 (4%)
Nephropathy 31 (62%) 30 (60%) 32 (65%) 29 (62%)
Renal Tubule, Degeneration 2 (4%)
Renal Tubule, Hyperplasia 1 (2%)
Renal Tubule, Necrosis 1 (2%) 1 (2%)
Transitional Epithelium, Hyperplasia 1 (2%)
Urinary Bladder (48) (50) (49) (46)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE FEMALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Inflammation, Chronic 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 50 50 50 50
Early Deaths
Natural Death 6 4 11 4
Moribund Sacrifice 8 13 14 9
Survivors
Terminal Sacrifice 36 33 25 37
Animals Examined Microscopically 50 50 50 50
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (43) (40) (38) (43)
Degeneration, Hyaline 1 (3%)
Inflammation, Suppurative 1 (2%) 2 (5%)
Epithelium, Hyperplasia 1 (3%)
Intestine Large, Cecum (45) (47) (44) (47)
Inflammation, Chronic 1 (2%)
Intestine Small, Duodenum (44) (47) (41) (48)
Epithelium, Hyperplasia 1 (2%)
Intestine Small, Ileum (44) (46) (41) (48)
Peyer's Patch, Hyperplasia 1 (2%)
Liver (50) (50) (50) (50)
Amyloid Deposition 1 (2%)
Angiectasis 1 (2%) 1 (2%)
Basophilic Focus 3 (6%) 4 (8%) 1 (2%) 1 (2%)
Congestion, Focal 1 (2%)
Degeneration, Fatty 1 (2%) 2 (4%) 1 (2%)
Eosinophilic Focus 11 (22%) 10 (20%) 7 (14%) 6 (12%)
Hematopoietic Cell Proliferation 1 (2%) 3 (6%) 2 (4%)
Hepatodiaphragmatic Nodule 1 (2%)
Infiltration Cellular, Mast Cell 1 (2%)
Inflammation, Chronic 1 (2%) 1 (2%) 3 (6%)
Necrosis 5 (10%) 5 (10%) 5 (10%) 5 (10%)
Vacuolization Cytoplasmic 1 (2%) 1 (2%) 1 (2%)
Bile Duct, Cyst 1 (2%) 1 (2%) 1 (2%)
Centrilobular, Degeneration 1 (2%)
Centrilobular, Necrosis 1 (2%)
Serosa, Fibrosis 1 (2%) 1 (2%)
Mesentery (3) (4) (2) (2)
Congestion 1 (25%)
Hemorrhage 1 (25%)
Fat, Necrosis 3 (100%) 3 (75%) 2 (100%) 1 (50%)
Pancreas (50) (48) (48) (50)
Atrophy 8 (16%) 3 (6%) 4 (8%) 8 (16%)
Basophilic Focus 1 (2%) 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 8
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Hyperplasia 1 (2%)
Hypertrophy 2 (4%)
Salivary Glands (50) (50) (49) (50)
Inflammation, Suppurative 2 (4%)
Stomach, Forestomach (50) (49) (48) (50)
Inflammation 1 (2%)
Ulcer 1 (2%)
Epithelium, Hyperplasia 2 (4%) 2 (4%) 1 (2%) 1 (2%)
Stomach, Glandular (50) (48) (46) (49)
Inflammation, Suppurative 2 (4%)
Necrosis 1 (2%) 1 (2%)
Epithelium, Hyperplasia 1 (2%)
Tooth (1) (1) (1)
Developmental Malformation 1 (100%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (50) (50) (49) (50)
Cardiomyopathy 44 (88%) 48 (96%) 46 (94%) 47 (94%)
Mineralization 1 (2%)
Atrium, Thrombosis 1 (2%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (50) (49) (48) (50)
Hemorrhage 1 (2%)
Hyperplasia 8 (16%) 11 (22%) 10 (21%) 5 (10%)
Hypertrophy 24 (48%) 29 (59%) 27 (56%) 30 (60%)
Capsule, Hyperplasia 1 (2%) 1 (2%)
Adrenal Medulla (50) (49) (48) (50)
Hyperplasia 1 (2%) 2 (4%) 2 (4%)
Islets, Pancreatic (50) (48) (48) (50)
Hyperplasia 1 (2%) 6 (13%) 3 (6%) 4 (8%)
Parathyroid Gland (36) (39) (31) (35)
Hyperplasia 1 (3%)
Pituitary Gland (47) (47) (46) (47)
Pars Distalis, Cyst 1 (2%)
Pars Distalis, Hyperplasia 3 (6%) 2 (4%)
Thyroid Gland (50) (50) (49) (50)
Follicular Cell, Hyperplasia 20 (40%) 19 (38%) 12 (24%) 15 (30%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 9
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
Peritoneum (1)
Inflammation 1 (100%)
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (50) (50) (49) (50)
Angiectasis 1 (2%)
Granuloma Sperm 2 (4%) 2 (4%)
Hyperplasia, Atypical 1 (2%)
Inflammation, Chronic 3 (6%) 2 (4%) 1 (2%) 2 (4%)
Penis (1) (1)
Capillary, Inflammation, Suppurative 1 (100%)
Preputial Gland (49) (50) (48) (50)
Cyst 6 (12%) 7 (14%) 8 (17%) 6 (12%)
Hyperplasia 1 (2%)
Inflammation 6 (12%) 6 (12%) 7 (15%) 11 (22%)
Prostate (48) (47) (47) (47)
Hyperplasia 2 (4%) 1 (2%) 1 (2%)
Inflammation, Chronic 1 (2%)
Inflammation, Suppurative 2 (4%) 1 (2%) 1 (2%) 3 (6%)
Seminal Vesicle (50) (48) (47) (49)
Congestion 1 (2%)
Inflammation, Chronic 1 (2%) 2 (4%)
Inflammation, Suppurative 1 (2%)
Testes (50) (50) (49) (50)
Atrophy 2 (4%) 4 (8%) 9 (18%) 4 (8%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (50) (50) (49) (50)
Angiectasis 1 (2%)
Hyperplasia 2 (4%) 2 (4%) 2 (4%) 2 (4%)
Hyperplasia, Histiocytic 1 (2%)
Infiltration Cellular, Mast Cell 1 (2%)
Infiltration Cellular, Megakaryocyte 2 (4%)
Lymph Node (2) (3) (2) (2)
Iliac, Hyperplasia 1 (50%) 1 (50%)
Iliac, Pigmentation 1 (50%)
Lymph Node, Bronchial (31) (37) (32) (36)
Hyperplasia 1 (3%) 5 (14%) 3 (9%) 2 (6%)
Lymph Node, Mandibular (32) (33) (32) (34)
Hyperplasia 1 (3%)
Infiltration Cellular, Mast Cell 1 (3%)
Lymph Node, Mesenteric (46) (47) (45) (48)
a Number of animals examined microscopically at site and number of animals with lesion
Page 10
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Angiectasis 2 (4%) 1 (2%) 1 (2%)
Congestion 1 (2%) 1 (2%)
Hematopoietic Cell Proliferation 1 (2%) 1 (2%)
Hyperplasia 4 (9%) 4 (9%) 3 (7%) 2 (4%)
Inflammation, Chronic 1 (2%)
Lymph Node, Mediastinal (34) (37) (39) (34)
Hyperplasia 3 (9%) 2 (5%) 1 (3%) 2 (6%)
Spleen (50) (48) (49) (50)
Amyloid Deposition 1 (2%)
Hematopoietic Cell Proliferation 11 (22%) 13 (27%) 11 (22%) 8 (16%)
Hyperplasia, Lymphoid 3 (6%) 3 (6%) 1 (2%) 1 (2%)
Infiltration Cellular, Mast Cell 1 (2%)
Infiltration Cellular, Mononuclear Cell 1 (2%)
Infiltration Cellular, Histiocyte 1 (2%)
Pigmentation, Melanin 1 (2%)
Thymus (30) (35) (32) (36)
Atrophy 1 (3%) 1 (3%) 2 (6%)
Epithelial Cell, Hyperplasia 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (50) (50) (49) (50)
Inflammation, Chronic Active 1 (2%) 1 (2%)
Prepuce, Inflammation, Chronic Active 4 (8%) 3 (6%) 4 (8%) 6 (12%)
Prepuce, Inflammation, Suppurative 1 (2%)
Subcutaneous Tissue, Inflammation, Focal,
Granulomatous 2 (4%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (50) (50) (50) (50)
Degeneration 1 (2%)
Fibrous Osteodystrophy 2 (4%) 1 (2%)
Inflammation, Chronic 1 (2%)
Skeletal Muscle (1) (1)
Hemorrhage 1 (100%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (50) (50) (49) (50)
Gliosis 1 (2%)
Meninges, Infiltration Cellular, Mast Cell 1 (2%)
Meninges, Inflammation, Chronic 1 (2%)
____________________________________________________________________________________________________________________________________
a Number of animals examined microscopically at site and number of animals with lesion
Page 11
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (50) (49) (48) (50)
Hyperplasia 1 (2%) 3 (6%) 6 (13%) 41 (82%)
Inflammation, Suppurative 1 (2%) 1 (2%)
Epiglottis, Hyperplasia 8 (16%) 2 (4%)
Epiglottis, Metaplasia, Squamous 26 (53%) 37 (77%) 49 (98%)
Lung (50) (50) (49) (50)
Hematopoietic Cell Proliferation 1 (2%)
Hemorrhage 4 (8%)
Infiltration Cellular, Histiocyte 2 (4%) 16 (32%) 9 (18%) 9 (18%)
Inflammation, Chronic 1 (2%)
Alveolar Epithelium, Hyperplasia 2 (4%) 1 (2%) 6 (12%) 2 (4%)
Alveolar Epithelium, Metaplasia 32 (64%) 36 (73%) 49 (98%)
Artery, Inflammation 2 (4%)
Perivascular, Infiltration Cellular 1 (2%)
Nose (50) (50) (49) (50)
Atrophy 1 (2%)
Infiltration Cellular, Mast Cell 1 (2%)
Inflammation, Suppurative 2 (4%) 6 (12%) 10 (20%) 8 (16%)
Metaplasia, Squamous 1 (2%) 2 (4%) 3 (6%) 1 (2%)
Nasolacrimal Duct, Inflammation, Suppurative 1 (2%) 2 (4%) 1 (2%)
Olfactory Epithelium, Atrophy 3 (6%) 5 (10%) 3 (6%) 10 (20%)
Olfactory Epithelium, Degeneration, Hyaline 1 (2%) 1 (2%) 1 (2%) 2 (4%)
Olfactory Epithelium, Metaplasia 1 (2%) 2 (4%)
Respiratory Epithelium, Degeneration, Hyaline 11 (22%) 13 (26%) 11 (22%) 41 (82%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
None
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (49) (50) (49) (50)
Hydronephrosis 1 (2%) 1 (2%) 2 (4%) 3 (6%)
Inflammation, Chronic 1 (2%)
Inflammation, Suppurative 1 (2%) 2 (4%) 2 (4%)
Metaplasia, Osseous 2 (4%) 1 (2%)
Nephropathy 44 (90%) 48 (96%) 44 (90%) 46 (92%)
Cortex, Cyst 1 (2%)
Papilla, Necrosis 1 (2%) 1 (2%)
Renal Tubule, Hyperplasia 1 (2%) 3 (6%) 3 (6%) 3 (6%)
Renal Tubule, Necrosis 1 (2%)
Urinary Bladder (50) (49) (46) (49)
Calculus Gross Observation 1 (2%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 12
NTP Experiment-Test: 05158-04 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: CHRONIC MOLYBDENUM TRIOXIDE Date: 04/04/96
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 02:35:23
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 10 MG/M3 30 MG/M3 100
MG/M3
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Inflammation, Chronic Active 2 (4%) 2 (4%)
Inflammation, Suppurative 2 (4%) 1 (2%)
Transitional Epithelium, Hyperplasia 1 (2%) 2 (4%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 13
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------